Galectin Therapeutics Inc. (FRA:PHPN)

Market Cap	153.57M +96.7%
Revenue (ttm)	n/a
Net Income	-31.91M
EPS	-0.50
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	15
Open	2.680
Previous Close	2.560
Day's Range	2.480 - 2.680
52-Week Range	1.050 - 5.800
Beta	n/a
RSI	31.37
Earnings Date	Mar 31, 2026

About Galectin Therapeutics

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Ther...

• Industry: Pharmaceutical Preparations
• Founded: 2000
• Employees: 15
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PHPN

Financial Performance

Financial numbers in USD